Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
Leukemia Research|February 29, 2016
Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemiaJean-Baptiste Fraison, Arsène Mekinian, Eric Grignano, et al.
Leukemia Research|December 20, 2014
Azacitidine for the treatment of relapsed and refractory AML in older patientsRaphael Itzykson, Sylvain Thépot, Céline Berthon, et al.
American Journal of Hematology|May 29, 2015
Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosisCharles Herbaux, Nicolas Duployez, Catherine Badens, et al.
Blood|August 11, 2011
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trialThorsten Braun, Raphael Itzykson, Aline Renneville, et al.
Blood|February 6, 2008
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 casesJean-Jacques Kiladjian, Francisco Cervantes, Franck W G Leebeek, et al.
Leukemia|October 7, 2021
Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AMLMatthieu Duchmann, Orianne Wagner-Ballon, Thomas Boyer, et al.
Leukemia & Lymphoma|August 26, 2017
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)José Falantes, Lisa Pleyer, Sylvain Thépot, et al.
Haematologica|May 28, 2016
A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agentsSylvain Thépot, Raouf Ben Abdelali, Sylvie Chevret, et al.
Blood|December 19, 2009
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experienceLionel Adès, Agnes Guerci, Emmanuel Raffoux, et al.
Blood|October 14, 2010
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidineRaphael Itzykson, Sylvain Thépot, Bruno Quesnel, et al.
Pageof 8